Home » Newsletters » BioWorld Science

BioWorld Science

July 28, 2022

View Archived Issues

Medshine Discovery identifies new CREBBP and/or p300 inhibitors

Shionogi discovers 5-HT2A receptor antagonists and/or inverse agonists

New galectin-3 inhibitors synthesized at Galecto Biotech

Jiangsu Chia Tai Tianqing Pharmaceutical Group patents G12C mutant GTPase KRAS inhibitors

IDP Discovery Pharma describes new VEGF inhibitors

M2-mAChRs as therapeutic targets for treating substance use disorders

Discovery of a new class of PDE4B inhibitors with activity in adjuvant-induced arthritis model

RAP-103 studies show potential of biphasic function opioid signaling modulators for use in analgesia

Step Pharma's CTPS1 inhibitor STP-938 cleared to enter clinic for T-cell and B-cell lymphomas

Tonix and KEMRI collaborate to advance TNX-801 as vaccine for monkeypox and smallpox

Neuron-like cells are glioblastoma's evil mastermind

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 23, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
Psychedelic space expanding on Trump’s EO
BioWorld
Timothy Leary is dead, but he could be on the outside looking in with a smile on his face as U.S. President Donald Trump’s latest executive order (EO) fuels a...
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...